Neurological symptoms may be the presenting feature in lupus, sarcoidosis, vasculitis, and other rheumatic diseases, notes this review. Treatment may also cause neurological side effects including demyelination, tremor, and psychosis.
Confirming the high pneumonia risk in lupus patients, researchers in Spain have found that it may precede the onset of the immune disorder. Their biological studies suggest that a particular underlying immune abnormality may explain both.
Movantik (naloxegol), taken once daily, blocks opioid receptors in the gut but does not cross the blood-brain barrier to affect opioid analgesia. It is expected to be available sometime in the first half of 2015.
Reanalyzing randomized trials by different methods, including one about scleroderma and another involving fibrositis, has changed their conclusions. The authors of this analysis argue for more openness when reporting trial data.
A large international team has honed in on the fragment of the complement receptor that decreases the risk for lupus. This has allowed them to offer a plausible explanation for why B cells target certain regions of double-stranded DNA after encountering debris from dying cells.